Defibrillators news | Breaking defibrillators news

News

Advertisers:

Boston Scientific's shares fall

...The profit was cut a further $26 million, or 2 cents per share, from other special charges, mostly from Guidant.Excluding such one-time items in both comparable periods, Boston Scientific said its first-quarter profit was $295 million, or 20 cents per share, down from $415 million, or 50 cents per share, in the year-ago period.First-quarter sales of Boston Scientific's Taxus drug-coated stent fell 26 percent to $468 million from $633 million a year ago.

Drug-coated stent sales have fallen off amid concerns that the devices may put patients at slightly higher risk for blood clots than older bare-metal stents.A study released in March created more trouble for stent makers by questioning whether the tiny mesh-metal devices are more effective than less-costly drug therapy at treating patients with clogged coronary arteries who don't face imminent risk of heart attack.Taxus had accounted for about 40 percent of Boston Scientific's overall revenue before the company acquired Guidant.Jim Tobin, Boston Scientific...